Go to POSTERS presentations ...
 

Oral and Invited presentations

    Presenting author # Title
  Gerding, D. INV1 KEYNOTE LECTURE - MILESTONES IN C. difficile RESEARCH
  Bouza, E. INV2 THE SPECTRUM OF C. difficile INFECTION (CDI) IN A GENERAL HOSPITAL. CASES AND SITUATIONS FROM THE REAL LIFE
  Riley, T. INV3 THE “ONE HEALTH” PARADIGM AND C. difficile
    Martín-Burriel, I. OP1 COMPARATIVE GENOME ANALYSIS OF Clostridium difficile STRAINS ISOLATED FROM DOMESTIC AND WILD ANIMALS REVEALS HIGH SIMILARITY WITH HUMAN STRAINS 
    Banks, A. OP2 COMMUNITY ASSOCIATED Clostridium difficile INFECTION (CDI) IN SCOTLAND – A SENTINEL STUDY
    Cairns, M. OP3 THE GLOBAL PHYLOGENY OF Clostridium difficile TOXIN A-B+  PCR RIBOTYPE 017
  McBride, S. INV4 NOVEL REGULATORY MECHANISMS CONTROL SPORULATION INITIATION IN C. difficile
    Salgado, P. OP4 THE MOTHER CELL TO FORESPORE CHANNEL HAS A CENTRAL ROLE IN SPORE MORPHOGENESIS, PROTEIN LOCALISATION AND PEPTIDOGLYCAN REMODELING
  Sorg, J. OP5 SPORE CORTEX HYDROLYSIS PRECEDES DPA RELEASE DURING C. difficile SPORE GERMINATION
  Pedneault, L. OP6 A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A Clostridium difficile VACCINE ADMINISTERED WITH OR WITHOUT ALUMINUM HYDROXIDE, IN A 3-DOSE REGIMEN IN HEALTHY ADULTS AGED 50 TO 85 YEARS 
  Therien, A. OP7 EPITOPES AND MECHANISMS OF ACTION OF THE Clostridium difficile TOXIN-NEUTRALIZING ANTIBODIES ACTOXUMAB AND BEZLOTOXUMAB
    Quemeneur, L. OP8 Clostridium difficile TOXOID VACCINE CONFERS CROSS- PROTECTION AGAINST PREVALENT CIRCULATING C. difficile VARIANT STRAINS IN NON-CLINICAL SETTINGS
    von Eichel-Streiber, A. OP9 DIFFERENTIAL SYSTEMIC AND MUCOSAL ANTI-TOXIN RESPONSES AMONG PATIENTS INFECTED WITH THE EPIDEMIC 027 STRAIN OF C. difficile
    Bajaj-Elliott, M. OP10 Clostridium difficile-INDUCED ER STRESS PROMOTES MACROPHAGE NLRP3 MEDIATED INFLAMMASOME ACTIVATION  
  Guery, B. INV5 TREATMENT OF CDI - PRESENT AND FUTURE
  Louie, T.  INV6 PRACTICAL ASPECTS OF FECAL MICROFLORA TRANSPLANTATION (FMT) FOR CDI
  Fitzpatrick, F. INV7 THE CARROT OR STICK?  USING HEALTHCARE-ASSOCITED C. difficile INFECTION RATES AS A PERFORMANCE MANAGEMENT TOOL
  Dubberke, E. INV8 TRANSMISSION AND FUTURE PREVENTION STRATEGIES
  Khanafer, N. OP11 FACTORS ASSOCIATED WITH SEVERE Clostridium difficile INFECTION ACCORDING TO 4 DIFFERENT SEVERITY DEFINITIONS
    Ivarsson, M. OP12 THERAPEUTIC POTENTIAL OF SMALL MOLECULE TRIGGERS OF PRE-EMPTIVE C. difficile TOXIN B AUTO-PROTEOLYSIS
  Barbut, F. INV9 DIAGNOSIS OF Clostridium difficile INFECTIONS: WHEN AND HOW?
  Janoir, C. INV10 C. difficile VIRULENCE FACTORS
    Corver, J. OP13 A NOVEL SECRETED METALLOPROTEASE (CD2830) FROM Clostridium difficile CLEAVES SPECIFIC PROLINE SEQUENCES IN LPXTG CELL SURFACE PROTEINS
    Kirk, J.A. OP14 THE Clostridium difficile S-LAYER: A MULTI-FUNCTIONAL VIRULENCE FACTOR AND ANTI-BACTERIAL TARGET
    Sekulovic, O. OP15 THE PHASE-VARIABLE CELL WALL PROTEIN CwpV CONFERS PHAGE RESISTANCE TO Clostridium difficile
  Spigaglia, P. INV11 ANTIBIOTIC RESISTANCE IN C. difficile – RECENT ADVANCES
    Faulds-Pain, A. OP16 INVESTIGATING THE POST-TRANSLATIONAL MODIFICATION OF THE Clostridium difficile FLAGELLIN
    Peltier, J. OP17 CYCLIC-DI-GMP REGULATES PRODUCTION OF SORTASE B SUBSTRATES OF Clostridium difficile AND THEIR SURFACE EXPOSURE THROUGH ZMPI PROTEASE-MEDIATED CLEAVAGE
  Young V.  INV12 C. difficile INFECTION: THE TANGLED WEB OF EPITHELIUM, MICROBIOTA AND PATHOGEN
  Carlucci, C. OP18 CHARACTERIZATION OF A DEFINED MICROBIAL ECOSYSTEM THERAPEUTIC FOR THE TREATMENT OF Clostridium difficile INFECTION
  Govoni, G. OP19 AVIDOCIN-CDs: TARGETABLE, MICROBIOTA-FRIENDLY BACTERICIDAL AGENTS FOR TREATMENT AND PREVENTION OF CDI 
  Chilton, C. OP20 POSSIBLE FAECAL MICROBIOTA MEDIATED INHIBITION OF THE BIOACTIVITY OF Clostridium difficile INFECTION (CDI) ANTIBIOTIC TREATMENT AGENTS